Abbott Q4 revenue $11.5B, adj EPS $1.32; FY2022 adj EPS guidance at least $4.70

ABBOTT LABORATORIES

2021-FY EPS reported $3.94 revenue$43,075,000,000

Q4 2021 GAAP diluted EPS $1.11; adjusted diluted EPS $1.32; sales $11.5B (+7.2% reported, +7.7% organic).
Full-year 2021 adjusted diluted EPS $5.21 (+42.7% YoY); total sales $43.1B (+24.5% reported).
COVID-19 testing sales $2.3B in Q4, $7.7B full year; company distributed over 1.4 billion tests since pandemic began.
FY2022 guidance: GAAP EPS at least $3.43, adjusted EPS at least $4.70; COVID testing sales forecast $2.5B.
Quarterly dividend of $0.47 per share declared, payable Feb. 15, 2022; marks 50 consecutive years of dividend increases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.